Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma

被引：0

作者：

Yasuyuki Mizutani

Tadashi Iida

Eizaburo Ohno

Takuya Ishikawa

Fumie Kinoshita

Yachiyo Kuwatsuka

Miwa Imai

Shinobu Shimizu

Toshihisa Tsuruta

Atsushi Enomoto

Hiroki Kawashima

Mitsuhiro Fujishiro

机构：

[1] Nagoya University Graduate School of Medicine,Department of Gastroenterology and Hepatology

[2] Nagoya University Graduate School of Medicine,Department of Pathology

[3] Nagoya University Hospital,Department of Advanced Medicine

[4] Nagoya University Hospital,Department of Endoscopy

[5] The University of Tokyo,Department of Gastroenterology, Graduate School of Medicine

来源：

BMC Cancer | / 22卷

关键词：

Cancer stroma; Tumour microenvironment; Cancer-associated fibroblasts; Cancer-restraining CAFs; Meflin; ISLR; AM80; Tamibarotene; MIKE-1;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma
Mizutani, Yasuyuki
Iida, Tadashi
Ohno, Eizaburo
Ishikawa, Takuya
Kinoshita, Fumie
Kuwatsuka, Yachiyo
Imai, Miwa
Shimizu, Shinobu
Tsuruta, Toshihisa
Enomoto, Atsushi
Kawashima, Hiroki
Fujishiro, Mitsuhiro
BMC CANCER, 2022, 22 (01)
[2] SAFETY AND EFFICACY OF AM80 IN PATIENTS WITH ADVANCED PANCREATIC CANCER: A STUDY PROTOCOL FOR AN OPEN-LABEL PHASE I/II INVESTIGATOR-INITIATED CLINICAL TRIAL BASED ON A DRUG REPOSITIONING APPROACH THAT REPROGRAMS THE TUMOUR STROMA
Mizutani, Yasuyuki
Iida, Tadashi
Ohno, Eizaburo
Ishikawa, Takuya
Fujishiro, Mitsuhiro
Kawashima, Hiroki
GASTROENTEROLOGY, 2022, 162 (07) : S310 - S310
[3] Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study
Li, Ning
Li, Zhi
Fu, Qiang
Zhang, Bin
Zhang, Jian
Wan, Xiang-Bin
Lu, Chao-Min
Wang, Jin-Bang
Deng, Wen-Ying
Ma, Yi-Jie
Bie, Liang-Yu
Wang, Meng-Yu
Li, Jing
Xia, Qing-Xin
Wei, Chen
Luo, Su-Xia
INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (04) : 2071 - 2084
[4] Anti-PD-1 antibody therapy for epithelial skin malignancies An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
Ishii, Maki
Hirai, Ikuko
Tanese, Keiji
Fusumae, Takayuki
Nakamura, Yoshio
Fukuda, Keitaro
Uchi, Hiroshi
Kabashima, Kenji
Otsuka, Atsushi
Yokota, Kenji
Yamazaki, Naoya
Namikawa, Kenjiro
Fujimura, Taku
Takenouchi, Tatsuya
Yamamoto, Yuki
Nishiguchi, Mana
Sato, Yasunori
Amagai, Masayuki
Funakoshi, Takeru
MEDICINE, 2020, 99 (44) : E22913
[5] A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
Yan, Min
Yuan, Peng
Ouyang, Quchang
Cheng, Ying
Han, Guohui
Wang, Dewei
Ran, Li
Sun, Tao
Zhao, Da
Bai, Yuju
Yang, Shun'e
Wang, Xiaojia
Wu, Rong
Zeng, Xiaohua
Yao, Herui
Ji, Xuening
Jiang, Jun
Hu, Xiaohua
Lin, Haifeng
Zheng, Liping
Zhu, Zhitu
Ge, Wei
Yang, Junlan
Cui, Tongjian
Zhang, Xiaozhi
Lu, Fangyang
Li, Wenhui
Xu, Hongyan
Kang, Mafei
Gong, Ping
Zou, Liqun
Liu, Jiang
Zhang, Hongliang
Yu, Hao
Xu, Binghe
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[6] Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial
Zhao, Xianzhi
Xiao, Yu-Tian
Yang, Yue
Ye, Yusheng
Chang, Yifan
Jiang, Lingong
Eftekhar, Md
Ren, Shancheng
Zhang, Huojun
CANCER CONTROL, 2022, 29
[7] Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer:: an open-label randomised phase II study
Spano, Jean-Philippe
Chodkiewicz, Catherine
Maurel, Joan
Wong, Ralph
Wasan, Harpreet
Barone, Carlo
Letourneau, Richard
Bajetta, Emilio
Pithavala, Yazdi
Bycott, Paul
Trask, Peter
Liau, Katherine
Ricart, Alejandro D.
Kim, Sinil
Rixe, Olivier
LANCET, 2008, 371 (9630): : 2101 - 2108
[8] Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial
Huang, Haichao
Wang, Tao
Li, Wei
Wu, Zhun
Wang, Xuegang
Xing, Jinchun
Chen, Bin
Zhang, Kaiyan
BMC CANCER, 2025, 25 (01)
[9] Letter to the editor for the article 'Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study'
Wang, Lexin
Wu, Qibiao
Chi, Hao
Yang, Guanhu
INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (09) : 6026 - 6027
[10] Induction of Cure in Early Arthritis (I CEA): study protocol for an investigator-initiated randomized single-blind clinical trial with open-label extension to compare three treatment strategies in patients with newly diagnosed undifferentiated arthritis
Bergstra, S. A.
van Ouwerkerk, L.
Nevins, I. S.
van der Pol, J. A.
Helmich, G. S.
Hest, I.
van Veen, A.
Bos, R.
Goekoop-Ruiterman, Y. P. M.
Vonkeman, H. E.
Bijsterbosch, J.
de Jong, P. H. P.
Guler-Yuksel, M.
Bohringer, S.
Huizinga, T. W. J.
van Gaalen, F. A.
TRIALS, 2024, 25 (01)

← 1 2 3 4 5 →